2016-03-01
Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5
Publication
Publication
European Urology : Official Journal of the European Association of Urology , Volume 69 - Issue 3 p. e43- e44
Additional Metadata | |
---|---|
doi.org/10.1016/j.eururo.2015.07.024, hdl.handle.net/1765/85472 | |
European Urology : Official Journal of the European Association of Urology | |
Organisation | Department of Medical Oncology |
van Soest, R. J., de Morrée, E., Kweldam, C., Wiemer, E., Mathijssen, R., de Wit, R., & van Weerden, W. (2016). Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5. European Urology : Official Journal of the European Association of Urology, 69(3), e43–e44. doi:10.1016/j.eururo.2015.07.024 |